1

A Functional Genomics Pipeline to Identify High-Value CpG Dinucleotides in the Human Methylome

Andréanne Morin[1,17], Emma E. Thompson[1,17], Britney A. Helling[1,17], Lyndsey E. Shorey-Kendrick[2],

Pieter Faber[3], Tebeb Gebretsadik[4], Leonard B. Bacharier[5], Meyer Kattan[6], George T. O'Connor[7],

Katherine Rivera-Spoljaric[8], Robert A. Wood[9], Kathleen C. Barnes[10], Rasika A. Mathias[11],

Matthew C. Altman[12], Kasper Hansen[13], Cindy T. McEvoy[14], Eliot R. Spindel[2], Tina Hartert[4], Daniel

J. Jackson[15], James E. Gern[15], Chris G. McKennan[16,18,*], and Carole Ober[1,18,*] on behalf of program

collaborators for Environmental Influences on Child Health Outcomes and Children's Respiratory

and Environmental Workgroup

[1] Department of Human Genetics, University of Chicago, Chicago, IL 60637

[2] Division of Neuroscience, Oregon National Primate Research Center, Oregon Health and
Science University, Beaverton, OR 97006

[3] Genomics Core, University of Chicago, Chicago, IL 60637

[4] Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232

[5] Department of Pediatrics, Monroe Carell Jr Children's Hospital at Vanderbilt University Medical
Center, Nashville, TN 37203

[6] Department of Pediatrics, Columbia University Medical Center, New York, NY 10032

[7] Pulmonary Center, Boston University School of Medicine, Boston, MA 02118

[8] Department of Pediatrics, Washington University, St. Louis, MO 63110

[9] Department of Pediatrics, Johns Hopkins University, Baltimore, MD 21287

[10] Department of Medicine, University of Colorado Denver, Aurora, CO 80045

[11] Department of Medicine, Johns Hopkins University, Baltimore, MD 21224

[12] Systems Immunology Division, Benaroya Research Institute Systems, Seattle, WA 98101;
Department of Medicine, University of Washington, Seattle, WA 98195

[13] Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University,
Baltimore, MD 21205

[14] Department of Pediatrics, Oregon Health and Science University, Portland, OR 97239

[15] Department of Pediatrics, University of Wisconsin School of Medicine and Public Health,
Madison, WI 53792-9988

[16] Department of Statistics, University of Pittsburgh, Pittsburgh, PA 15260

[17] A.M., E.E.T., and B.A.H. contributed equally to this work.

[18] C.M.K. and C.O. jointly supervised this work.

*Corresponding authors:

Carole Ober, PhD
Department of Human Genetics, University of Chicago
920 E. 58th St, Chicago, IL 60637
Email: c-ober@genetics.uchicago.edu

Christopher Gordon McKennan, PhD
Department of Statistics, University of Pittsburgh
1826 Wesley W. Posvar Hall
230 S Bouquet St, Pittsburgh, PA 15260
Email: CHM195@pitt.edu

67 **This PDF file includes:**

68   Main Text
69   Figures 1 to 4

Abstract

DNA methylation of cytosines at CpG dinucleotides is a widespread epigenetic mark; but

genome-wide variation has been relatively unexplored due to the limited representation of

variable CpGs on commercial high-throughput arrays. To explore this hidden portion of the

epigenome, we combined whole-genome bisulfite sequencing with *in silico* evidence of function

to design a custom array of high-value CpGs. We focused these studies in airway epithelial cells

from children with and without allergic asthma because these cells mediate the effects of

inhaled microbes, pollution and allergens on asthma and allergic disease risk. Epigenome-wide

association studies (EWAS) of allergic sensitization revealed enrichments for CpGs with

intermediate methylation levels that were more likely to be correlated with the expression of

their target genes and associated with allergic sensitization in children of diverse ancestries

compared to CpGs on commercial arrays. Overall, our study revealed signature features of

functional CpGs and unveiled a wealth of DNA methylation variation at functional CpG sites that

have been ignored in previous EWAS.

86
87   **Introduction**
88
Epigenetics refers to modifications of DNA molecules that do not alter the DNA sequence but

play important roles in regulating gene expression. Environmental exposures can directly modify

epigenetic marks in the human genome (1), and epigenetic responses can mediate the effects of

exposures on gene expression (2) and disease risk (3). Thus, the epigenome may contribute

directly to disease risk or be sites of gene-environment interactions, providing both

complementary data and mechanistic insights, respectively, to genome-wide association studies

(GWAS). The most common epigenetic mark in the human genome is methylated cytosines at

CpG dinucleotides and the availability of high-throughput array-based platforms to measure

DNA methylation has led to an explosion of epigenome-wide association studies (EWAS) (4). The

most used commercial array, the InfinityMethylationEPIC BeadChip (Illumina, Inc., San Diego,

CA), interrogates up to 850,000 CpGs, but this comprises <5% of CpGs in the human genome.

Because the selection of CpGs on the EPIC array was agnostic with respect to disease or tissue

types, findings to date may represent just the tip of the iceberg with an abundance of yet

unknown functional CpG sites contributing to disease risk.

The goal of our study was to develop and validate a custom DNA methylation array

enriched for CpGs in airway epithelial cells that are likely to be functional and associated with

asthma and allergic diseases in populations of diverse ancestries. We focused on airway

epithelial cells because of their critical role in responding to inhaled microbes, pollution and

allergens and mediating their downstream effects on asthma and allergic disease risk (5, 6). An

overview of our study design is shown in **Figure 1**.

109
110
111 **Results**

112
Identifying Differentially Methylated Regions in Whole-Genome Bisulfite Sequences

We performed whole-genome bisulfite sequencing (WGBS) in airway epithelial cell DNA from 20

African American children (10 with allergic asthma, 10 without asthma or allergies; 11 years old)

from the Urban Environment and Childhood Asthma (URECA) cohort (7) and 19 European

American young adults (9 with allergic asthma, 10 without asthma or allergies; 18-20 years old)

from the Childhood Origins of Asthma (COAST) cohort (8). After quality control (QC) (see

Methods), analyses for differentially methylated regions (DMRs) between the asthma/allergy

cases and non-asthma/non-allergy controls were performed in the African American sample, the

European American sample, and the combined sample (see **Methods** for additional details).

Overall, we identified 16,611 DMRs that included 199,473 CpGs (**Supplementary Table 1**).

Selecting High-Value CpGs for an Asthma&Allergy Custom DNA Methylation Array

Our goal was to develop a custom array with 50,000 probes for CpGs that would complement

and serve as a "booster" for the EPIC array for studies of asthma and allergic diseases. Our

selection criteria involved three steps (**Supplementary Fig. 1**; also see **Methods**). Briefly, we first

identified a set of CpGs based on prior evidence of association with asthma or allergic diseases

(atopic dermatitis/eczema, allergic rhinitis/hay fever, and food allergy) from three categories of

studies. The first category included the 199,473 CpGs within DMRs from the WGBS study

described above, the second included 19,057 CpGs associated with asthma or allergic diseases in

17 previous EWAS (**Supplementary Table 2**), and the third included 570,350 CpGs at 140 GWAS

loci (**Supplementary Table 3**). We then removed CpGs on the EPIC array, in ENCODE blacklisted

regions (9), and those that overlapped with a common single nucleotide polymorphism (SNP) in

1000 Genomes European (CEU) or African (YRI) populations. To further prioritize the remaining

696,225 CpGs, in the second step we considered their overlap with functional annotations,

requiring that CpGs within DMRs overlap with at least three annotations or other category of

prior evidence, CpGs from prior EWAS overlap with at least one annotation or other category of

prior evidence, and CpGs at GWAS loci overlap with at least four annotation categories or other

category of prior evidence. After removing duplicates, 92,024 high-value CpGs remained; 53,700

passed the Illumina array design step and, in the third step, we pruned to 44,047 by selecting

CpGs from all categories with the highest number of functional annotations. After manufacture

and array QC, 37,863 CpGs targeted by 42,192 probes remained (**Supplementary Table 4**).

The distributions of CpGs on the Custom and EPIC arrays are shown by annotation

category in **Figure 2A**. Of note, 90% of CpGs on the Custom array overlapped with a

transcription factor binding site (TFBS), and 94% overlapped with a predicted enhancer,

compared to 56% and 54% of the EPIC array CpGs, respectively (Fisher exact test [FET] p<10^{-16}

for both comparisons). Moreover, compared to EPIC CpGs, Custom CpGs were enriched in

introns (52.8% vs. 47.2%) and exons (24.0% vs. 22.1%) and depleted in intergenic regions (23.1%

vs. 30.7%) and 5'UTRs (6.8% vs. 7.4%) (FET p<10^{-4} for all comparisons) **(Figure 2B)**. The CpGs on

the Custom array proportionally represented DMR-CpGs from the three DMR studies in WGBS

and from the three categories of prior evidence (**Supplementary Fig. 2**).

Evaluating methylation patterns of CpGs on the Custom Array

To assess the reproducibility of methylation measures of CpGs on the Custom array, we

compared β values in airway epithelial cell DNA in the WGBS to the same CpGs on the Custom

and the EPIC arrays for the subset of individuals with all three (19 URECA subjects) or two (17

COAST subjects) measures. We included CpGs with at least 10 WGBS reads that overlapped with

an array CpG that passed QC. This resulted in 502,229 CpGs for the WGBS and EPIC array

comparison in URECA and 24,744 and 20,861 CpGs for the WGBS and Custom array comparison

in URECA and COAST, respectively. The β distribution plots were similar and highly correlated

between CpGs measured by both WGBS and the arrays (Spearman's p<2.2x10^{-16} for each)

(**Supplementary Fig. 3**). Notably, however, compared to the EPIC array, CpGs on the Custom

array were depleted for hypermethylated CpGs and enriched for intermediate methylated (IM)

CpGs (β values 20-80%).

To more broadly assess EPIC and Custom array DNA methylation patterns, we compared

the distributions of CpG β values across different tissues using available data for the EPIC array

in DNA from airway epithelial cells (this study), airway smooth muscle cells (10), and buccal

swabs, placenta cells, and cord blood (11), and for the Custom array in DNA from nasal epithelial

cells and nasal lavage cells from URECA children, and buccal cells, cord blood cells, or placenta

tissue from infants in the Vitamin C to Decrease the Effects of Smoking in Pregnancy on Infant

Lung Function (VCSIP) cohort (11). The β distributions were similar across cell sources for CpGs

on the EPIC array (**Figure 3A**) but showed varying patterns between cell types on the Custom

array (**Figure 3B**). Whereas an average of 68% (range: 60-79%) of CpGs on the EPIC array were

either hypomethylated (0-20%) or hypermethylated (80-100%) in all six cell types, most CpGs on

the Custom array (66% in nasal epithelial cells and 52% on average across cell types) were IM

CpGs with depletions of β values between both 0-10% (24% in nasal epithelial cells and 29% on

average) and 90-100% (10% in nasal epithelial cells and 20% on average). In fact, the β value

distributions of CpGs on the EPIC array in nine GTEx tissues are remarkably similar to those

reported here (**Supplementary Fig. 4**) (12). We confirmed that differences between the two

arrays were attributable to the selection criteria we used for designing the array. Using the same

criteria, high-value CpGs on the EPIC array also showed a depletion of both hypomethylated and

hypermethylated CpGs and an enrichment for IM CpGs (**Supplementary Fig. 5**).

EWAS of Allergic Sensitization in 280 Multi-Ancestry Children using the Custom and EPIC

Arrays

Our ultimate goal was to develop a DNA methylation array that could detect asthma- or allergy-

associated differential methylation that is missed by the content on the EPIC array. Allergic

sensitization (AS) is an IgE response to allergens (13) and a crucial step in the development of

allergic diseases and common phenotypes of asthma (14-16). We conducted an EWAS of AS in

airway epithelial cell DNA collected from 280 11-year old URECA children using the Custom and

the EPIC arrays. We used the percent of positive skin prick tests (14 airborne and oral allergens)

as a quantitative measure of AS (see **Methods**). The demographic and clinical description of the

URECA children is shown in **Supplementary Table 5** and **Supplementary Fig. 6**.

Following QC of the array (see **Methods**), we performed two EWAS of AS in the same

URECA children using CpGs on the EPIC or Custom array. In each analysis, we included as

covariates sex, percent epithelial cells, the first 3 ancestry principal components (PCs), and

latent factors to adjust for additional unwanted variation (17, 18) (see **Methods**). Using a q-

value threshold of 0.05, the EWAS of AS revealed 1,805 differentially methylated CpGs (DMCs)

using the EPIC array and 193 DMCs using the Custom array (**Figure 4A-B**), revealing an

enrichment for AS DMCs on the Custom compared to the EPIC array (0.50% vs. 0.23% of CpGs on

each array, respectively; FET p<2.2x10^{-16}). Among the DMCs on the EPIC array, 295 (16%) were

high-value EPIC CpGs, a significant enrichment compared to 3.5% of high-value CpGs among all

CpGs on the EPIC array (FET p<2.2x10^{-16}). In contrast to the different β distributions of CpGs on

each array (**Figure 3A**), the β distributions of DMCs from the two arrays were similar (**Figure 4A-**

B; middle panels), showing a near complete depletion of both hypomethylated and

hypermethylated CpGs and an enrichment of IM CpGs among AS DMCs in airway epithelial cells.

The DMCs on both arrays were distributed across the autosomes (**Supplementary Fig.**

7A-B), however, DMCs on the Custom array showed spikes of association signals compared to

the sparse distribution of DMCs on the EPIC array. In fact, 50% of DMCs on the Custom array are

within 100bp of the next nearest DMC compared to only 3% of DMCs on the EPIC array (**Figure**

4D). Regional clustering of DMCs on the Custom array provides greater confidence in and

internal validation of EWAS results.

Most of the functional annotation categories of DMCs were proportional to all CpGs on

each array (**Figure 2A and 2C**; see **Figure 2** legend for all statistical test results). However, DMCs

from both arrays were depleted at transcription start sites and in areas of open chromatin

compared to all CpGs on the arrays. Among the primary criteria (prior evidence), CpGs in DMRs

were modestly enriched for DMCs compared to all CpGs on the Custom array. Similarly, DMCs in

prior EWAS studies of asthma and allergic diseases were modestly enriched on the Custom array

but significantly enriched on the EPIC array. In contrast, CpGs at GWAS loci for asthma and

allergic diseases were not enriched among DMCs on the Custom array and only modestly

enriched on the EPIC array compared to all CpGs on the array. The genomic locations of the

DMCs were proportional to all CpGs on the arrays (**Figure 2B and 2D**).

Because AS is an important step in the development of childhood asthma, we next

asked whether AS DMCs were also associated with allergic asthma. Considering only the AS

DMCs on the EPIC array, 1,155 (64%) were also associated with allergic asthma at q-value <0.05

(1,805 tests). Among the AS DMCs on the Custom array, 115 (60%) were also associated with

allergic asthma at q-value <0.05 (193 tests). The effect sizes were significantly correlated

between AS DMCs and allergic asthma DMCs (r=0.68). Among the CpGs that were DMCs for

both AS and allergic asthma, all showed the same direction of effect; among all AS DMCs, 93%

showed the same direction of effect with allergic asthma (r=0.84) (**Figure 4E**).

Validating the Custom Array in the INSPIRE Cohort

The URECA cohort is diverse with respect to ancestry but includes <1% non-Hispanic White

children (7). Therefore, to both replicate results of the EWAS in URECA children and assess the

performance of the Custom array in a primarily non-Hispanic White population, we studied 5- to

7-year-old children from the Infant Susceptibility to Pulmonary Infections and Asthma Following

RSV Exposure (INSPIRE) study (19). INSPIRE infants were enrolled following delivery into this

population-based longitudinal study in central Tennessee. An EWAS was performed using the

Custom array and nasal epithelial cell DNA from 474 children with measures of AS (proportion of

positive SPT to 13 inhaled allergens). The demographic and clinical characteristics of the INSPIRE

children are shown in **Supplementary Fig. 6** and **Supplementary Table 5**. See **Methods** for

further descriptions of the sample, allergens tested, and processing and QC of the array data.

The AS EWAS model in INSPIRE included as covariates sex, parent-reported race or

ethnicity, DNA concentration, and latent factors to adjust for unwanted variation (17) (see

Methods). At a q-value threshold of <0.05 based on 37,261 tests, 85 CpGs on the Custom array

were DMCs (0.2% of CpGs). The β distribution of the DMCs (**Figure 4C**) and the spikes of

associations (**Supplementary Fig. 7**) were similar to those observed in URECA. Among the AS

DMCs in INSPIRE, 38% were also allergic asthma DMCs (q-value<0.05 based on 85 tests), all with

the same direction of effect. Among all AS DMCs in INSPIRE, 93% had the same direction of

effect with allergic asthma (**Figure 4F)**. Moreover, among the AS DMCs in URECA, 25 (13%) were

also AS DMCs in INSPIRE, which was a highly significant enrichment (p<2.2x10^{-16}), and all had

concordant directions of effect. Finally, the effect sizes of the 253 CpGs that were DMCs in

either the URECA or INSPIRE AS EWAS were highly correlated (r=0.61; p<2.2x10^{-16}) (**Figure 4G**).

The high reproducibility of EWAS results in two cohorts demonstrates that the high-value CpGs

on the Custom array identified AS DMCs that are robust to ancestry, ascertainment strategies,

age at sampling, and geography.

Regional association plots combining results of the three AS EWAS for the 10 most

significant DMCs in the EPIC and Custom EWAS in URECA are presented in **Supplementary**

Materials, along with three exemplary regions and their associations with gene expression

(**Supplementary Materials**, pages 4-10).

Evaluating the Biological Significance of DMCs in Airway Epithelial Cells

Because nearly all CpGs on the Custom array were selected to overlap with a TFBS or enhancer

mark, we expected these CpGs to be correlated with the expression of genes in airway epithelial

cells more often than CpGs on the EPIC array (20). To test this, we used gene expression data

(16) in the same cells as those used for DNA methylation studies in 249 of the URECA children

and defined two sets of genes from among the 15,551 genes detected as expressed in these

cells: the nearest gene to each CpG and the promoter capture Hi-C (pcHi-C)-defined target gene

in airway epithelial cells (see **Methods**). The latter identifies putative enhancers that physically

interact with target gene promoters and account for the 3-dimensional structure of the genome

that allows for distal regulatory elements to interact with and regulate the activity of promoters

over large distances (e.g., up to 1 Mb or more), which are often not the nearest gene. Among

the nearest expressed genes to DMCs on the Custom (98 genes) and EPIC (1,449 genes) arrays,

63 were the nearest gene to CpGs on both arrays. Among the pcHi-C target genes for DMCs on

the Custom (245 genes) or EPIC (1,155 genes) arrays, 95 were target genes of CpGs on both

arrays. Thus, although no CpGs overlapped between the arrays, 101 of nearest or pcHi-C target

genes were shared on both arrays (**Supplementary Table 6**). The 318 nearest or pcHi-C target

genes on the Custom array that were expressed in airway epithelial cells were enriched in 16

pathways (FDR <0.05), including "Th1 and Th2 cell differentiation," "JAK-STAT signaling," "Th17

cell differentiation," and "Viral protein interaction with cytokine and cytokine receptor"

(**Supplementary Table 7**). In contrast, the 2,366 nearest or pcHi-C target genes on the EPIC array

that were expressed in airway epithelial cells were not enriched for any pathways (smallest FDR

= 0.13). These findings further demonstrate that the CpGs on the Custom array are enriched in

pathways relevant to asthma and allergic disease.

For each CpG-gene pair, we tested for correlation between DNA methylation and

expression levels of their nearest and pcHi-C target gene(s) to identify expression quantitative

methylation (eQTM) CpGs. We used a linear model that included sex, percent epithelial cells,

and three ancestry PCs as covariates (FDR <0.05). Significantly more CpGs on the Custom array

were eQTMs with their nearest gene (23%) or pcHi-C target gene (16%) compared to CpGs on

the EPIC array (11% and 9% respectively; FET $p<2.2 \times 10^{-16}$ in both analyses). The high-value EPIC

CpGs were also enriched for eQTMs compared to all EPIC CpGs (20% and 12%, respectively; FET

$p<2.2 \times 10^{-16}$ in both analyses). Although more AS DMCs were eQTMs on both arrays, significantly

more were on the Custom compared to the EPIC array (nearest gene 35% vs. 20% [FET p =

0.0019] and pcHi-C 22% vs 15% [FET p = 0.0082], respectively) (**Supplementary Table 8**). The β

distributions for DMCs on the Custom and EPIC arrays that were eQTMs were further enriched

for IM CpGs and depleted of CpGs at the extremes of the distribution (**Figure 4** and

Supplementary Fig. 8).

Examples of correlations between methylation and gene expression levels for DMCs are

shown in **Supplementary Materials** (pages 4-10) for three representative EWAS loci.

296
297   **Discussion**
298
The epigenome plays a critical role in regulating gene expression in a context-specific manner,

such as in specific cell types or in the presence of environmental exposures or disease states.

DNA methylation, for example, is responsive to disease promoting exposures in both in *in vitro*

cell models (10, 21-23) and *ex vivo* cells from individuals who are healthy and with disease (1,

24-27). Yet the DNA methylome has been underexplored and largely limited to the CpGs on

commercial arrays. As a result, it is unknown whether the 800,000 or fewer CpGs interrogated in

nearly all EWAS studies to date include CpGs most relevant to any specific exposure, disease, or

cell type. Here, we addressed this question by designing a custom Allergy&Asthma DNA

methylation array with 37,863 high-value CpGs that are not included on the commercial EPIC

array. Our study design allowed us to make important observations regarding features of high-

value CpGs and to propose a pipeline that can be used to prioritize CpGs from among the more

than 28 million in the human genome in future studies.

Although we did not select CpGs based on methylation levels, those selected by our

pipeline were significantly enriched for IM CpGs (β values 20-80%). The CpGs that were DMCs

and eQTMs were further enriched for IM CpGs on both the EPIC and Custom arrays, suggesting

that this one feature is a signature of high-value, variable and functional CpGs in the genome. In

contrast, the non-IM CpGs may be more functionally constrained and less responsive to

environmental perturbations. Our results are supported by previous WGBS studies showing that

IM CpGs were more likely to be tissue specific, to vary between individuals, and to play

important roles in gene regulation (20, 28). Our study further revealed that CpGs with

intermediate levels of methylation are also more likely to be associated with AS, an important

clinical phenotype that reflects both an immune response to past allergen exposures (13) and a

risk factor for the development of asthma and allergic diseases (14-16). Indeed, AS DMCs were

highly enriched for allergic asthma DMCs. Although the CpGs on the custom array were overall

enriched for IM CpGs, AS DMCs were further enriched, with a near complete depletion of very

hypomethylated (0-20% methylation) and very hypermethylated (80-100%) CpGs. This

important observation was further supported by EWAS results using the EPIC array. Whereas

EPIC array CpGs are enriched for hypomethylated and hypermethylated CpGs in all tissues, the

EPIC DMCs were depleted for CpGs at both extremes and enriched for IM CpGs, similar to the

DMCs on the custom Allergy&Asthma array. We further showed that the 26,905 CpGs on the

EPIC array that passed our filtering pipeline were also enriched for IM CpGs and enriched among

AS DMCs: 16.3% of the DMCs in the AS EWAS were among the high-value EPIC CpGs compared

to 3.4% of all CpGs on the EPIC array. These results, combined with previous studies (20, 28),

could justify filtering CpGs on the EPIC array to include just IM CpGs (β=20-80%) to enrich for

functional CpGs and increase power to detect DMCs associated with exposure or disease

outcomes. Our data support this suggestion. Using all CpGs on the EPIC array and a q-value

threshold of 0.05, we identified 1,805 DMCs (0.23% of all CpGs). However, when we include only

IM CpGs in the EWAS, we identified 2,182 DMCs (0.70% of all IM CpGs), more than three times

the proportion of DMCs among tested CpGs. Finally, DMCs that were eQTMs were further

enriched for IM CpGs (**Figure 4** and **Supplementary Fig. 8**), supporting their role in gene

regulation.

In addition to the enrichment of IM CpGs on the Custom compared to the EPIC array,

the patterns of associations with AS on the two arrays were notable. Whereas DMCs on the EPIC

are more sparsely distributed throughout the genome, the DMCs on the Custom show spikes of

association, analogous to GWAS peaks. The spatial organization among DMCs on the Custom

provides confirmatory evidence for their veracity, which is not available for CpGs on the EPIC

array (**Figure 4D**). Another distinguishing feature of the DMCs on the Custom array were their

enrichment in exons and depletions in intergenic regions compared to DMCs on the EPIC array.

This is consistent with results of an earlier study that observed enrichments of IM CpGs in exons,

where exon expression at those sites correlated with DNA methylation (20).

The CpGs included on the custom Allergy&Asthma array were selected based on prior

evidence of associations with asthma or allergic diseases using three classes of evidence: within

a DMR in our WGBS study, in a previous published EWAS, or at published GWAS loci. Overall,

62% of CpGs on the custom array were selected from DMRs compared to 1.6% of all CpGs on

the EPIC array, yet the DMR CpGs were enriched among DMCs on both the custom (77.2%) and

EPIC (3.9%) arrays. Because we excluded all CpGs on the EPIC from the Custom array, few

previous EWAS CpGs were on the Custom array, although we still observed a modest

enrichment of EWAS CpGs among DMCs on the Custom array (1.9% overall vs. 4.1% of DMCs)

and a highly significant enrichment among DMCs on the EPIC array (4.9% overall vs. 21.7% of

DMCs). These represent replications of results from previous EWAS of asthma and allergic

phenotypes. In contrast to these two categories of prior evidence, CpGs at asthma and allergy

GWAS loci were very modestly enriched among EPIC array DMCs but not enriched, and even

slightly depleted, among the Custom array DMCs. In a WGBS in 25 different cell and tissue types,

Elliott et al. (20) showed that IM CpGs were more likely to be allele independent than to show

allele-specific methylation. Busche et al. (28) conducted a WGBS study in adipose and blood cells

from twins and concluded that non-genetic effects were mainly tissue specific and located in

gene regions, consistent with the features of CpGs on the Custom array, whereas CpGs with

genetic effects were shared across tissues and more likely to be intergenic, consistent with

features of CpGs on the EPIC array. They concluded that non-shared environments accounted

for most of the variance in methylation levels. Our findings of a lack of enrichment of DMCs at

GWAS loci, but enrichments for IM CpGs and for AS DMCs in exons suggest that inter-individual

variation for IM CpGs on the Custom array may be the set of more plastic CpGs in the human

genome and better reflect the effects of environmental exposures than of genetics.

Nonetheless, our study still revealed examples of AS DMCs at important GWAS loci (e.g., *IRF1* on

chromosome 5, *CLEC16A* on chromosome 16, and *HDAC7/VDR* on chromosome 12)

(**Supplementary Results**; pages 6-9).

In summary, our study revealed high-value functional CpGs in airway epithelial cells that

are not interrogated on the EPIC array. Our pipeline identified 92,024 high-value CpGs after

excluding 26,905 high-value CpGs on the EPIC array. Therefore, among the >28 million CpG sites

in the genome, less than 0.5% are likely to be functional, or high value, in any particular tissue or

disease/environment context. The Custom array, which included about half of the non-EPIC

high-value CpGs in airway epithelial cells, indicated that associations with AS and allergic asthma

were robust to race/ethnicity, ascertainment, age, and geography. We suggest that similar

pipelines can be used to identify high-value CpGs for other disease groups or specific

environmental exposures leading to the discovery of currently invisible portions of the

epigenome that are relevant to human health.

385
386
387   **Materials and Methods**
388
Cohorts Included in WGBS or EWAS Studies

Three longitudinal birth cohort studies were included in these studies. All studies were approved

by the Institutional Review Boards of each of the institutions recruiting subjects; for each cohort,

one parent or guardian provided informed consent for their child's participation. Informed

consent was obtained from participants in the COAST cohort after their 18th birthday.

The URECA study is an observational birth cohort study initiated in 2005 in Baltimore,

Boston, New York City, and St. Louis under the NIAID-funded Inner City Asthma Consortium (7).

Either the pregnant mother or the father of their unborn child had a history of asthma, allergic

rhinitis, or eczema. Asthma was assessed at age 10 according to a definition that considered

symptoms, diagnosis by a health care provider, and measurements of pulmonary function, as

described (16). Skin prick testing was performed at age 10 (255 subjects) or age 7 (25 subjects)

and included the following allergens: mouse epithelia, dog epithelia, *Dermatophagoides fainae*

(mite), *Dermatophagoides pteronyssinus* (mite), cat hair, rat epithelia, American/German

cockroach mix, German cockroach, *Alternaria tenuis* (mold), *Aspergillus* mix, ragweed mix, tree

pollen (oak or birch), *Penicillium Notatum/Pennicillium Chrysogenum*, and Timothy grass. Nasal

brushings were obtained at age 11 years, as described (16). Twenty African American children

were selected for the WGBS studies (10 with asthma and allergic disease [3 females, 7 males],

10 without asthma or allergic disease [3 females, 7 males]), and 280 unrelated children were

included in the EWAS using both the Custom and EPIC arrays. The characteristics of the 280

URECA participants are described in **Supplementary Table 5**.

The COAST study is an observational birth cohort study initiated in 1998 in Madison,

Wisconsin (8). Pregnant women were recruited in the third trimester of pregnancy if the mother

or the father had a history of asthma or allergic diseases. Asthma was assessed beginning at age

6 years. Children were diagnosed with asthma if they fulfilled at least one of the following

criteria: (1) physician-diagnosed asthma; (2) frequent albuterol use for coughing or wheezing

episodes as prescribed by a physician; (3) use of a prescribed daily controller medication; (4) an

implemented step-up plan, including use of albuterol or inhaled corticosteroids during illness as

prescribed by a physician; (5) use of prednisone for an asthma exacerbation. Nasal brushings

were obtained at ages 18-20 years, as described (29). Twenty participants of European American

ancestry were selected for the WGBS studies (10 with asthma and allergic disease [5 males, 5

females], 10 without asthma or allergic disease [5 males, 5 females]).

The INSPIRE study is a population-based observational birth cohort of healthy infants in

central Tennessee (19). Children were followed longitudinally for the outcomes of asthma and

allergic diseases. Flocked nasal swabs were obtained at age 5-6 years and samples were stored

at –80°C in RNA lysis buffer. RNA and DNA were isolated from the swabs using the Qiagen

AllPrep DNA/RNA kit. Subjects were tested for the following thirteen allergens: dog, cat,

Dermatophagoides pteronyssinus and *Dermatophagoides farinae* mix, American/German

cockroach, *Penicillium Notatum*/*Penicillium Chrysogenum*, *Alternaria Tenuis*, *Cladosporum*

Herbarum, *Aspergillus* mix, Ragweed mix, Eastern 6 Tree mix, K-O-T Grass mix, Maple/Box Elder

mix, and Weed mix. The characteristics of the 474 unrelated INSPIRE children included in the

EWAS are described in **Supplementary Table 5**.

Cohorts included in the Cross-Tissue Comparison Studies

In addition to studying nasal epithelial cell DNA with the Custom array in URECA, we included

results from studies of the Custom array in DNA from nasal lavage cells (n=96), buccal cells

(n=96), placenta (n=96) and cord blood (96). The nasal lavage cell DNA was isolated from URECA

subjects around age 13 (mean = 13.4 years, range = 12.8 - 14.9 years) using the QIAamp DNA

Micro Kit. The buccal, placenta and cord blood cell DNA was collected from 96 participants in

the VCSIP cohort (11). Placental DNA was extracted from powdered tissue under liquid nitrogen,

using the QIAcube for automated nucleic acid extraction. Cord blood DNA was extracted from

200μL of whole blood using the QIAamp DNA Mini Kit and the QIAcube, and buccal DNA was

extracted from buccal swabs following proteinase K digestion using the Maxwell 16 Blood DNA

Extraction Kit and the Maxwell 16 Instrument for automated nucleic acid extraction.

Whole Genome Bisulfite Sequencing and DMR Studies

DNA (250 ng) from participants in the URECA and COAST cohorts was transferred to the

University of Chicago Genomics Facility. Bisulfite conversion and sequencing were conducted

using the EZ DNA Methylation-Gold Kit library prep and the Swift Biosciences Accel-NGS Methyl-

seq DNA library kit, respectively. Samples were sequenced to a minimum of 330 million reads on

the Illumina NovaSEQ6000 (S4 flowcell). Adapters were removed from sequence reads using

trimgalore (30) prior to mapping the reads using bismark (version 0.18.2) (9) and the hg19

reference assembly. Bismark was further used to remove duplicate reads and call methylation

values. Prior to DMR analyses, CpGs were removed if they overlapped with a common SNP

(minor allele frequency [MAF] >0.05) in 1000 genomes CEU or YRI populations (31) or in

Blacklisted regions (32). Variant calling from WGBS was performed using the biscuit algorithm,

which also identified sample swaps and contamination. The variant calls from WGBS were

compared to either array-based genotypes (COAST) or whole genome-sequence-based

genotypes (URECA). All variant calls matched with an accuracy of >95%, except for one

mismatched sample in COAST. The latter sample was excluded from further analysis, leaving 19

samples for analysis (9 allergic asthmatics and 10 non-asthma/non-allergic controls).

DMR analyses were conducted in the African American sample (n=20), the European

American sample (n=19), and the combined African American and European American sample

(n=39). The methylation data were then smoothed using BSmooth (33), and DMRs were called

using the bsseq package (version 1.14) (33). Only CpGs covered by at least 10 reads in 80% of

the cases and controls (AA only, EA only, and combined n=39) were included. T-statistics cutoffs

were based on 5% quantiles, and a maximum gap of 300bp was required between CpGs to

define a cluster, as recommended by BSmooth. To maximize the number of DMRs, we required

three or more CpGs per DMR and a minimum of 5% difference in methylation levels between

the allergy asthma cases and non-allergy, non-asthmatic controls. The union of DMRs between

analyses was assessed using the *reduce* function from the GenomicRanges R package (version

1.30).

Selection of CpGs for Custom Array

We first identified CpGs with a high likelihood of being associated with asthma and allergic

disease (**Supplementary Fig. 1**). In the first step, we prioritized regions with prior evidence of

association with asthma or allergic diseases (atopic dermatitis/eczema, allergic rhinitis/hay

fever, and food allergy) from three categories of studies. The first category included the 199,473

CpGs within the DMRs from the WGBS. The second category included CpGs from previous DNA

methylation studies (EWAS) of asthma or allergic diseases. For this, we conducted a literature

search for array-based studies of DNA methylation in asthma and allergic disease. We identified

15 studies that conducted 25 EWAS of asthma- or allergy-related phenotypes, five of which

were conducted in respiratory epithelium and 10 in blood (**Supplementary Table 2**). We also

included CpG sites for five additional genes from two candidate-gene DNA methylation studies

of food allergies; *FOXP3* (34) and *IL4*, *IL5, IL10* and *INFG* (35). In total, 19,057 unique DMCs were

identified. The third category included CpGs located within the 140 GWAS loci defined in two

recent large studies of adult-onset and childhood-onset asthma (36) and allergic diseases

(asthma, hay fever and eczema) (37) in UK Biobank subjects (38), which included nearly all the

loci reported in other GWAS in multi-ancestry populations. In total, the GWAS loci covered a

total of 570,350 CpG motifs. We also included CpGs for the *MALT1* gene that was significantly

associated with peanut allergy in a genome-wide interaction study (39). We next removed

duplicate CpGs from among the three categories of prior studies, CpGs on the EPIC array, CpGs

in ENCODE blacklist regions (9), and those in which the cytosine nucleotide overlapped with

common SNPs (MAF > 5%) in 1000 Genomes CEU or YRI populations (**Supplementary Table 4**). A

total of 696,225 CpGs remained for consideration in the second step.

To further prioritize the CpGs, in the second step we considered their overlap with six

functional annotations: 1) ENCODE (40) TFBSs from all cell types; 2-4) ROADMAP Epigenetics

(41) transcriptional start sites, poised enhancers and active enhancers from smooth muscle

(E078, E076, E103, E111), epithelial (E055, E056, E059, E061, E058), and blood cells (E062, E034,

E045, E044, E043, E039, E041, E042, E040, E037, E048, E038, E047, E029, E050, E032, E046); 5)

ATAC-seq in human cultured bronchial epithelial cells exposed to rhinovirus or a vehicle control

from asthmatic and non-asthmatic individuals (42), and 6) pcHi-C from *ex vivo* human bronchial

epithelial cells (42). We required that CpGs at DMRs overlapped with at least three functional

annotations or prior evidence (GWAS or EWAS), CpGs from previous EWASs overlapped with at

least one functional annotation or prior evidence (GWAS or DMR), and CpGs at GWAS loci

overlapped with at least four functional annotations or prior evidence (EWAS or DMR). Lastly,

we selected all remaining CpGs that were within both a GWAS locus and a DMR.

Of the 92,024 resulting high-value CpGs identified, 53,700 were amenable to the

Illumina design algorithm, and 44,047 CpGs targeted by 49,999 probes were selected by us for

manufacturing. Fourteen percent of the CpGs failed manufacturing, resulting in a Custom array

with 38,541 CpGs targeted by 43,605 probes. After removing probes with unknown origins and

those without genomic coordinates, 37,863 CpGs passed array QC. The locations of this final set

of CpGs, their selection among the three primary criteria, and their overlap with the annotation

categories are shown in Supplementary Dataset 1. Finally, we removed probes that included a

common SNP (MAF≥5%) within 3 bp of the CpG interrogation site, probes that failed the minfi

QC, and probes on the X chromosome, leaving 37,256 CpGs following both array and processing

QC**.**

RNA-sequencing studies in URECA

Protocols for processing samples for RNA-seq in nasal epithelial cells from the URECA children

have been described (16). Gene expression data were available in 249 of the children with DNA

methylation data. In these data, 15,643 genes were detected as expressed.

Estimation of genetic ancestry

Ancestry PCs were estimated in the URECA children using a set of 3,534 SNPs that were

genotyped in URECA and in reference panels from the 1000 Genomes Project (1KG; n=156)(31)

and the Human Genome Diversity Project (HGDP; n=52). European, West African, and East Asian

reference samples were randomly selected from CEU (n=52), YRI (n=52), JPT (n=26), and CHB

(n=26) samples, respectively, in the phase 3 1KG reference panel (31). Ancestry PCs were

calculated using PC-Air (43). The first two ancestry PCs for the URECA children in our study are

shown in **Supplementary Fig. 9**.

Processing Custom and EPIC array methylation data in URECA

DNA methylation was assessed using the Illumina Allergy&Asthma Custom BeadChip or the

Illumina Infinium MethylationEPIC BeadChip (Illumina, San Diego, CA) following bisulfite

conversion at the University of Chicago Genomics Facility. Methylation data from both arrays

were processed using minfi v1.29.1 (44). The annotation and manifest packages for the

Allergy&Asthma array can be found here:

https://github.com/hansenlab/IlluminaHumanMethylationAllergymanifest.

For the EPIC array, probes that failed (detection $P < 0.01$ in at least 25% of samples),

overlapped with known SNPs with MAF of at least 5% in African American or European

Americans, mapped to the X or Y chromosomes, overlapped ENCODE blacklist regions, or

mapped to multiple locations in a bisulfite-converted genome were removed. Raw probe values

were background corrected using preprocessIllumina(bg.correct="TRUE", normalize="no"), and

quantile normalization was performed using ENmix (v 1.30.01)

(https://doi.org/10.1186/s13148-021-01207-1), followed by SWAN (45) normalization. Samples

that failed sex checks using the getSex function in minfi were removed. DNA concentration,

collection site, array and plate showed batch effects by principal components analysis (PCA)

(46). The effects of collection site, array, and plate were removed using ComBat (47); DNA

concentration was removed using linear regression. We estimated unobserved variation in the

data correlated with our phenotype of interest (18) and included these latent factors in the

model (18). The first three ancestry PCs were also included as covariates to capture the effects

of admixture in the sample. After QC, we retained 789,290 (91.1%) of CpGs on the EPIC array for

analysis.

For the Custom array, probes that failed (detection $P < 0.01$ in at least 25% of samples),

contained a SNP with MAF of at least 5% in African American or European Americans within 3bp

of the CpG interrogation site, mapped to the X chromosome, or were missing genomic

coordinates were removed. Raw probe values were background corrected using

preprocessIllumina(bg.correct="TRUE", normalize="no"), and quantile normalization was

performed using ENmix. Additional probe-type normalization using SWAN was not applied

because the dye intensities for the methylated and unmethylated type I and type II probes had

very different distributions. DNA concentration, collection site, array, and plate showed batch

effects by PCA. The effects of site, plate, and chip were removed using ComBat, and DNA

concentration was removed using linear regression. We estimated unobserved variation in the

data that was not correlated with the phenotype of interest and included these latent factors in

the model. To account for regional differences in the density of Custom array CpGs on the

estimation of latent factors, we used the partition.params function in FALCO (17)

(https://github.com/chrismckennan) to partition groups of CpGs into independent units (default

size = 100 kb). The first three ancestry PCs were included as covariates to capture the effects of

admixture in the sample for analyses in URECA. After QC, we retained 37,256 (98.1%) CpGs on

the Custom array for analyses.

For comparison purposes, we filtered the CpGs on the EPIC array through the same

pipeline described above for selecting CpGs for the Custom array; we refer to these as "high-

value" EPIC CpGs. Of the 789,290 CpGs on the EPIC array, 26,905 (3.4%) were considered high-

value, similar in number to the 37,863 CpGs that passed QC on the Custom array

(Supplementary Dataset 2).

Processing Custom array methylation data in INSPIRE

The same pipeline used in URECA was used to process INSPIRE Custom methylation data.

Twenty-one probes failed *P*-value detection and were removed from the analysis. We estimated

sex using the X chromosome CpGs and removed five samples with discrepancies between these

classifications and reported sex. DNA concentration, collection year, plate, and array were

identified as having batch effects by PCA (**Supplementary Table 9**). The effects of collection

year, plate, and array were removed using ComBat, and DNA concentration was removed using

linear regression. Because DNA concentration was correlated with other variables, it was also

included as a covariate in the model, along with sex, parent-reported race/ethnicity, and latent

factors estimated using the same methods described above for URECA. A total of 37,261 CpGs

passed processing QC and were included in the analysis.

EWAS in the URECA and INSPIRE cohorts

For each EWAS we used the following models:

URECA: DNAm ~ proportion positive SPTs + sex + %epithelial cells + AncPCs$_{1-3}$ + LFs$_{1-n}$

INSPIRE: DNAm ~ proportion positive SPTs + sex + race/ethnicity + DNA concentration + LFs$_{1-n}$

For the URECA EWAS, we included 14 and 5 latent variables for the Custom (17) and

EPIC (18) arrays, respectively. Cell counts (300 cells/slide) were performed on each sample (16).

Because we did not have information on cell proportion or genetic ancestry for INSPIRE, we

included sex, parent-reported race/ethnicity, DNA concentration, and 21 latent factors as

covariates to adjust for cell composition, as well as other unwanted variation in the EWAS.

Analyses were performed in R (version 4.1.0) using limma v 3.50.0 (48, 49). To control the false

discovery rate, we used a q-value threshold of 0.05. The URECA EWAS sample included 19 of the

20 African American children in the WGBS studies and the 96 children shown in the cross-tissue

density plots of β distributions (**Figure 3**).

To assess the overlap of AS DMCs with allergic asthma DMCs, we tested the AS DMCs for

association with allergic asthma in URECA and INSPIRE. For these studies, we defined allergic

asthma cases as children with a diagnosis of asthma at age 10 (URECA) or age 6 (INSPIRE) <u>and</u>

sensitization to at least one allergen (N=62 and 22, respectively). Controls were defined as

children without a diagnosis of asthma (ever) and without any positive skin prick tests (n=76 and

271, respectively). We calculated q-values based on the 193 AS DMCs in URECA and the 85 AS

DMCs in INSPIRE. The overlaps of AS and allergic asthma cases and controls are shown in

Supplementary Fig. 10.

Correlations of methylation level with expression of nearest gene and target promoter capture

Hi-C gene

Correlations between methylation levels at each CpG with the expression levels of the nearest

gene and the pcHi-C target genes (42) were assessed using linear regression in both the full data

set (all CpGs that passed QC on each array) and in the DMCs. Comparisons were only assessed

for DMCs falling in "capture end regions" (± 1kb) that interacted with gene promoters (42). Sex,

ancestry PCs, and epithelial cell composition were included as covariates in the model. The

nearest gene was annotated using the GenomicRanges package v1.46.1 in R with the gene list

from the R biomaRt package v2.50.2 using ensemble GRCh37. A false discovery rate of 5% was

used to assess significance.

Pathway analysis

Pathway over-representation testing was performed with Advaita Bio's iPathwayGuide

(https://www.advaitabio.com/ipathwayguide) using KEGG Pathways (release 100.0+/11-12, Nov

2021). For the Custom and the EPIC arrays, the 318 and 2,366 genes, respectively, that were

either the nearest or pcHi-C target gene to a DMC, were entered as significant against a

background of all nearest genes to CpGs on each arrays that are expressed in NECs (n=14,049).

References

1.   M. Prunicki *et al.*, Air pollution exposure is linked with methylation of immunoregulatory
genes, altered immune cell profiles, and increased blood pressure in children. *Sci Rep*
11, 4067 (2021).
2.   Y. Li *et al.*, DNA methylation and transcriptome aberrations mediated by ERalpha in
mouse seminal vesicles following developmental DES exposure. *Proc Natl Acad Sci U S A*
115, E4189-E4198 (2018).
3.   E. W. Tobi *et al.*, DNA methylation as a mediator of the association between prenatal
adversity and risk factors for metabolic disease in adulthood. *Sci Adv* **4**, eaao4364
(2018).
4.   M. Li *et al.*, EWAS Atlas: a curated knowledgebase of epigenome-wide association
studies. *Nucleic Acids Res* **47**, D983-D988 (2019).
5.   S. T. Holgate, The sentinel role of the airway epithelium in asthma pathogenesis.
Immunol Rev **242**, 205-219 (2011).
6.   C. A. Akdis, The epithelial barrier hypothesis proposes a comprehensive understanding
of the origins of allergic and other chronic noncommunicable diseases. *J Allergy Clin*
Immunol **149**, 41-44 (2022).
7.   J. E. Gern *et al.*, The Urban Environment and Childhood Asthma (URECA) birth cohort
study: design, methods, and study population. *BMC Pulm Med* **9**, 17 (2009).
8.   R. F. Lemanske, Jr., The childhood origins of asthma (COAST) study. *Pediatr Allergy*
Immunol **13**, 38-43 (2002).
9.   F. Krueger, S. R. Andrews, Bismark: a flexible aligner and methylation caller for Bisulfite-
Seq applications. *Bioinformatics* **27**, 1571-1572 (2011).
10.   E. E. Thompson *et al.*, Cytokine-induced molecular responses in airway smooth muscle
cells inform genome-wide association studies of asthma. *Genome Med* **12**, 64 (2020).
11.   L. E. Shorey-Kendrick *et al.*, Impact of vitamin C supplementation on placental DNA
methylation changes related to maternal smoking: association with gene expression and
respiratory outcomes. *Clin Epigenetics* **13**, 177 (2021).

12.   M. Oliva *et al.*, Genetic regulation of DNA methylation across tissues reveals thousands
of molecular links to complex traits. *Research Square* https://doi.org/10.21203/rs.3.rs-
492596/v1 (2021).

13.   R. van Ree, L. Hummelshoj, M. Plantinga, L. K. Poulsen, E. Swindle, Allergic sensitization:
host-immune factors. *Clin Transl Allergy* **4**, 12 (2014).

14.   S. Illi *et al.*, The pattern of atopic sensitization is associated with the development of
asthma in childhood. *J Allergy Clin Immunol* **108**, 709-714 (2001).

15.   D. J. Jackson, J. E. Gern, R. F. Lemanske, Jr., The contributions of allergic sensitization
and respiratory pathogens to asthma inception. *J Allergy Clin Immunol* **137**, 659-665;
quiz 666 (2016).

16.   M. C. Altman *et al.*, Endotype of allergic asthma with airway obstruction in urban
children. *J Allergy Clin Immunol* 10.1016/j.jaci.2021.02.040 (2021).

17.   C. McKennan, Factor analysis in high dimensional biological data with dependent
observations. *arXiv:2009.11134v1* (2020).

18.   C. McKennan, D. L. Nicolae, Accounting for unobserved covariates with varying degree
of estimability in high dimensional experimental data. *Biometrika* **106**, 823-840 (2019).

19.   E. K. Larkin *et al.*, Objectives, design and enrollment results from the Infant
Susceptibility to Pulmonary Infections and Asthma Following RSV Exposure Study
(INSPIRE). *BMC Pulm Med* **15**, 45 (2015).

20.   G. Elliott *et al.*, Intermediate DNA methylation is a conserved signature of genome
regulation. *Nat Commun* **6**, 6363 (2015).

21.   A. Pacis *et al.*, Bacterial infection remodels the DNA methylation landscape of human
dendritic cells. *Genome Res* **25**, 1801-1811 (2015).

22.   J. Nicodemus-Johnson *et al.*, Genome-wide methylation study identifies an IL-13-
induced epigenetic signature in asthmatic airways. *Am J Respir Crit Care Med* **193**, 376-
385 (2016).

23.   M. M. Soliai *et al.*, Multi-omics colocalization with genome-wide association studies
reveals a context-specific genetic mechanism at a childhood onset asthma risk locus.
Genome Med **13**, 157 (2021).

24.   A. Cardenas *et al.*, Controlled human exposures to diesel exhaust: a human epigenome-
wide experiment of target bronchial epithelial cells. *Environ Epigenet* **7**, dvab003 (2021).

25.   E. S. Wan *et al.*, Cigarette smoking behaviors and time since quitting are associated with

676   differential DNA methylation across the human genome. *Hum Mol Genet* **21**, 3073-3082

677   (2012).

678   26.   K. M. Bakulski, J. Dou, N. Lin, S. J. London, J. A. Colacino, DNA methylation signature of

679   smoking in lung cancer is enriched for exposure signatures in newborn and adult blood.

680   *Sci Rep* **9**, 4576 (2019).

681   27.   S. Sikdar *et al.*, Comparison of smoking-related DNA methylation between newborns

682   from prenatal exposure and adults from personal smoking. *Epigenomics* **11**, 1487-1500

683   (2019).

684   28.   S. Busche *et al.*, Population whole-genome bisulfite sequencing across two tissues

685   highlights the environment as the principal source of human methylome variation.

686   *Genome Biol* **16**, 290 (2015).

687   29.   S. Basnet *et al.*, CDHR3 Asthma-Risk Genotype Affects Susceptibility of Airway

688   Epithelium to Rhinovirus C Infections. *Am J Respir Cell Mol Biol* **61**, 450-458 (2019).

689   30.   A. Kechin, U. Boyarskikh, A. Kel, M. Filipenko, cutPrimers: A New Tool for Accurate

690   Cutting of Primers from Reads of Targeted Next Generation Sequencing. *J Comput Biol*

691   **24**, 1138-1143 (2017).

692   31.   1000 Genomes Project Consortium *et al.*, A global reference for human genetic

693   variation. *Nature* **526**, 68-74 (2015).

694   32.   H. M. Amemiya, A. Kundaje, A. P. Boyle, The ENCODE Blacklist: Identification of

695   Problematic Regions of the Genome. *Sci Rep* **9**, 9354 (2019).

696   33.   K. D. Hansen, B. Langmead, R. A. Irizarry, BSmooth: from whole genome bisulfite

697   sequencing reads to differentially methylated regions. *Genome Biol* **13**, R83 (2012).

698   34.   L. Paparo *et al.*, Epigenetic features of FoxP3 in children with cow's milk allergy. *Clin*

699   *Epigenetics* **8**, 86 (2016).

700   35.   R. Berni Canani *et al.*, Differences in DNA methylation profile of Th1 and Th2 cytokine

701   genes are associated with tolerance acquisition in children with IgE-mediated cow's milk

702   allergy. *Clin Epigenetics* **7**, 38 (2015).

703   36.   M. Pividori, N. Schoettler, D. L. Nicolae, C. Ober, H. K. Im, Shared and distinct genetic risk

704   factors for childhood-onset and adult-onset asthma: genome-wide and transcriptome-

705   wide studies. *Lancet Respir Med* **7**, 509-522 (2019).

37.   A. Johansson, M. Rask-Andersen, T. Karlsson, W. E. Ek, Genome-wide association
analysis of 350 000 Caucasians from the UK Biobank identifies novel loci for asthma, hay
fever and eczema. *Hum Mol Genet* **28**, 4022-4041 (2019).

38.   C. Bycroft *et al.*, The UK Biobank resource with deep phenotyping and genomic data.
Nature **562**, 203-209 (2018).

39.   A. Winters *et al.*, The MALT1 locus and peanut avoidance in the risk for peanut allergy. *J
Allergy Clin Immunol* **143**, 2326-2329 (2019).

40.   Encode Project Consortium *et al.*, Expanded encyclopaedias of DNA elements in the
human and mouse genomes. *Nature* **583**, 699-710 (2020).

41.   Roadmap Epigenomics Consortium *et al.*, Integrative analysis of 111 reference human
epigenomes. *Nature* **518**, 317-330 (2015).

42.   B. A. Helling *et al.*, Altered transcriptional and chromatin responses to rhinovirus in
bronchial epithelial cells from adults with asthma. *Commun Biol* **3**, 678 (2020).

43.   M. P. Conomos, M. B. Miller, T. A. Thornton, Robust inference of population structure
for ancestry prediction and correction of stratification in the presence of relatedness.
Genet Epidemiol **39**, 276-293 (2015).

44.   M. J. Aryee *et al.*, Minfi: a flexible and comprehensive Bioconductor package for the
analysis of Infinium DNA methylation microarrays. *Bioinformatics* **30**, 1363-1369 (2014).

45.   J. Maksimovic, L. Gordon, A. Oshlack, SWAN: Subset-quantile within array normalization
for illumina infinium HumanMethylation450 BeadChips. *Genome Biol* **13**, R44 (2012).

46.   J. T. Leek *et al.*, Tackling the widespread and critical impact of batch effects in high-
throughput data. *Nat Rev Genet* **11**, 733-739 (2010).

47.   W. E. Johnson, C. Li, A. Rabinovic, Adjusting batch effects in microarray expression data
using empirical Bayes methods. *Biostatistics* **8**, 118-127 (2007).

48.   B. Phipson, S. Lee, I. J. Majewski, W. S. Alexander, G. K. Smyth, Robust Hyperparameter
Estimation Protects against Hypervariable Genes and Improves Power to Detect
Differential Expression. *Ann Appl Stat* **10**, 946-963 (2016).

49.   M. E. Ritchie *et al.*, limma powers differential expression analyses for RNA-sequencing
and microarray studies. *Nucleic Acids Res* **43**, e47 (2015).

735
736
737

Acknowledgments

Research reported in this publication was supported by the Environmental influences on Child

Health Outcomes (ECHO) program, Office of The Director, National Institutes of Health, under

Award Numbers U2COD023375 (Coordinating Center), U24OD023382 (Data Analysis Center),

U24OD023319 (PRO Core), UH3 OD023282 (COAST, INSPIRE, URECA) and UH3 OD023288

(VCSIP); and grants UM1 AI114271, UM1 AI160040, U19 AI62310, U19 AI095227, UL1 TR002243

P51 OD011092 and R01 HL104608.

The authors wish to thank our ECHO colleagues, the medical, nursing, and program staff, and

the children and families participating in the ECHO cohorts. We also acknowledge the

contribution of the following ECHO program collaborators:

ECHO Components – Coordinating Center: Duke Clinical Research Institute, Durham, NC: Smith

PB, Newby KL.

Author Contributions: A.M., E.E.T., B.A.H. performed all data analyses; A.M., E.E.T., B.A.H.,
C.G.M., and C.O. designed the study and wrote the manuscript; P.F. oversaw the laboratory
assays; L.E.S-K., T.G., L.B.B., M.K., G.T.O., K.R.S., R.A.W., C.T.M., E.R.S., T.H., D.J.J., and J.E.G.
provided clinical samples and information and consulted on study design; M.C.A. provided gene
expression data; K.C.B., R.A.M., and K.H. consulted on study design. All authors read,
commented on and approved the manuscript.

Competing Interest Statement: L.B.B. reports personal fees from GlaxoSmithKline
Genentech/Novartis, Merck, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca,
WebMD/Medscape, Sanofi/Regeneron, Vectura, Circassia, Elsevier, Kinaset, and Vertex outside
the submitted work. G.T.O. has received consulting fees from Dicerna and Menarini unrelated to
this work. R.A.W. has received grants from Aimmune, Astellas, DBV, Genentech, Novartis,
Regeneron, and Sanofi. K.C.B. is employed by Tempus Labs. M.C.A. has received consulting
fees from Regeneron outside the submitted work. D.J.J. reports grants and personal fees from
GlaxoSmithKline and Regeneron and personal fees from Pfizer, Sanofi, AstraZeneca, and Vifor
Pharma, outside the submitted work. J.E.G. is a paid consultant for AstraZeneca and Meissa
Vaccines Inc. and has stock options in Meissa Vaccines Inc.

Data Sharing Plans

The gene expression data used this study are available on the Gene Expression Omnibus (GEO)
repository (accession number GSE145505). The DNA methylation array data used in the EWAS
study are available in GEO (accession number in progress). The whole-genome bisulfite
sequencing data are available in dbGaP (in progress).

asthma and half without asthma or allergies). To select CpGs for the Custom array, we identified CpGs based on prior evidence of association

with asthma or allergic disease from three sources (see text and **Supplementary Fig. 1**). The CpGs were then prioritized based on their overlap

with functional annotations to ultimately design a Custom array with 42,192 probes for 37,863 CpGs. **(B)** Airway epithelial cell DNA was

hybridized to both the Custom array and the EPIC array for comparison, and β value distributions on the arrays were compared to the WGBS

data and across tissues using the Custom and EPIC array. **(C-D)** We validated the Custom array by performing an EWAS of allergic sensitization

(AS), examined correlations with the gene expression in the same cells, and replicated findings in a second cohort and with allergic asthma. **(E)**

The combined results of the Custom and EPIC arrays in the discovery cohort and of the Custom array in the replication cohort for known and

novel loci were examined in regional association plots.

Figure 2. Proportions of Custom and EPIC CpGs by primary criteria, functional annotation category, and genomic location. All comparisons

were performed with a Fisher's Exact Test. (**A**) Proportions of Custom CpGs that passed processing QC in URECA on each array by three primary

criteria and six functional annotation categories. CpGs on the Custom array were significantly enriched ($p<2.2\times10^{-16}$) in all categories compared

to the EPIC array with the exception of prior EWAS, in which they were depleted ($p<2.2\times10^{-16}$). (**B**) The distributions of CpGs by genomic location.

Compared to the EPIC, CpGs on the Custom array were enriched in introns and exons and depleted in intergenic regions and 5'UTRs ($p<10^{-4}$), but

did not differ in any other categories. (**C**) Proportions of Custom and EPIC DMCs from each array by three primary criteria and six functional

annotation categories. Compared to all CpGs, DMCs from both arrays were depleted at transcription start sites and in areas of open chromatin

(Custom $p=1.14\times10^{-7}$ and $p=4.11\times10^{-9}$; EPIC $p<2.2\times10^{-16}$ for both, respectively). DMRs were marginally enriched for DMCs compared to all CpGs

on the Custom array ($p=0.066$) but significantly enriched on the EPIC array ($p=1.54\times10^{-6}$). DMCs in prior EWAS studies of asthma and allergic

diseases were modestly enriched on the Custom array (FET $p=0.059$) and significantly enriched on the EPIC array ($p<2.2\times10^{-16}$). In contrast, CpGs

at GWAS loci for asthma and allergic diseases were not enriched among DMCs on the Custom array ($p=0.32$) and only modestly enriched on the

EPIC array ($p=0.042$). (**D**) The distribution of DMCs by genomic location. The distribution of DMCs on both arrays did not differ from the

distributions of all CpGs.

Figure 3. Cross-tissue comparisons of methylation levels on the EPIC and Custom arrays. Density distribution plots of methylation levels,

measured as β values, in 96 individuals after quantile (Custom) or quantile + SWAN (EPIC) normalizations (see **Methods**). The x-axis shows the

810   proportion of methylation at CpG sites on the EPIC (**A**) and Custom (**B**) arrays for each individual. All DNA methylation data were processed using

811   the same pipeline. The nasal epithelial cell DNA (EPIC and Custom) and nasal lavage cell DNA (Custom) were from the same randomly selected

812   96 URECA children with both the EPIC and Custom arrays in nasal epithelial cells. The buccal, placenta, and cord blood cells were from infants in

813   the VCSIP Study (see **Methods**).

Figure 4. Asthma EWAS results in URECA and INSPIRE children using the EPIC and Custom arrays. (A-C) <u>Upper panel</u>: Volcano plots showing the

log₂-fold change in methylation proportion (M-values) with and without allergic sensitization (x-axis) and the -log₁₀(P-value) from the EWAS (y-

axis). Significant DMCs at a q-value threshold of 0.05 are shown are shown in blue or purple (EPIC and filtered EPIC, respectively) in URECA, in

red (Custom) in URECA or turquoise (Custom) in INSPIRE. The number of DMCs that were hypermethylated or hypomethylated in the children

with AS are shown as up and down arrows, respectively in the figures. **(A-C)** <u>Middle panel</u>: Density plots of the DMCs in each EWAS. **(A-B)** <u>Lower</u>

<u>panel:</u> Density plots of CpGs that are eQTMs for their nearest genes. **D**) Distributions of DMCs to the next nearest DMC on the Custom (red) and

EPIC (blue) arrays. The distance to nearest DMC is shown on the x-axis; the proportion of DMCs in each distance bin is shown on the y-axis. **(E-F)**

Correlation of effect sizes (log fold change) of AS DMCs and allergic asthma in URECA and INSPIRE. The effect size of DMCs for AS (x-axis) and

allergic asthma (y-axis) are shown. Red or turquoise dots were associated with allergic asthma at a q-value threshold of 0.05 in URECA or

INSPIRE, respectively; black dots are AS-only DMCs. **(G)** Correlation of effect sizes (log fold change) between DMCs identified in the INSPIRE AS

EWAS (x-axis) and the URECA AS EWAS (y-axis). Red or turquoise points are AS DMCs only in URECA or INSPIRE, respectively, at a q-value

threshold of 0.05; black dots are AS DMCs in both at a q-value threshold of 0.05. The dashed lines in E-G are the correlation lines.